UK DHSC plans £39 million funding for antimicrobial resistance

22 May 2023
uk_london-1-

The UK Department of Health and Social Care (DHSC) proposes £39 million ($48.5 million) of funding for antimicrobial resistance (AMR) research through the Global AMR Innovation Fund (GAMRIF).

Of this new funding package, up to £24 million over four years has been awarded to bolster the UK’s partnership with CARB-X – a global AMR research initiative – to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world.

The UK has already given £20 million of its ringfenced Official Development Assistance (ODA) budget to the initiative which, together with other funders, has resulted in CARB-X in turn investing nearly £40 million into the UK’s world-leading science and innovation industry.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical